Menashe Idan, Anderson William F, Jatoi Ismail, Rosenberg Philip S
Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD 20852-7244, USA.
J Natl Cancer Inst. 2009 Jul 15;101(14):993-1000. doi: 10.1093/jnci/djp176. Epub 2009 Jul 7.
In the United States, a black-to-white disparity in age-standardized breast cancer mortality rates emerged in the 1980s and has widened since then.
To further explore this racial disparity, black-to-white rate ratios (RRs(BW)) for mortality, incidence, hazard of breast cancer death, and incidence-based mortality (IBM) were investigated using data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program on 244 786 women who were diagnosed with breast cancer from January 1990 through December 2003 and followed through December 2004. A counterfactual approach was used to examine the expected IBM RRs(BW), assuming equal distributions for estrogen receptor (ER) expression, and/or equal hazard rates of breast cancer death, among black and white women.
From 1990 through 2004, mortality RR(BW) was greater than 1.0 and widened over time (age-standardized breast cancer mortality rates fell from 36 to 29 per 100 000 for blacks and from 30 to 22 per 100 000 for whites). In contrast, incidence RR(BW) was generally less than 1.0. Absolute hazard rates of breast cancer death declined substantially for ER-positive tumors and modestly for ER-negative tumors but were persistently higher for blacks than whites. Equalizing the distributions of ER expression in blacks and whites decreased the IBM RR(BW) slightly. Interestingly, the black-to-white disparity in IBM RR(BW) was essentially eliminated when hazard rates of breast cancer death were matched within each ER category.
The black-to-white disparity in age-standardized breast cancer mortality was largely driven by the higher hazard rates of breast cancer death among black women, diagnosed with the disease, irrespective of ER expression, and especially in the first few years following diagnosis. Greater emphasis should be placed on identifying the etiology of these excess hazards and developing therapeutic strategies to address them.
在美国,年龄标准化乳腺癌死亡率的黑人与白人差异在20世纪80年代出现,并自此不断扩大。
为进一步探究这种种族差异,利用美国国立癌症研究所监测、流行病学和最终结果计划的数据,对1990年1月至2003年12月期间被诊断为乳腺癌并随访至2004年12月的244786名女性的死亡率、发病率、乳腺癌死亡风险和基于发病率的死亡率(IBM)的黑人与白人比率(RRs(BW))进行了调查。采用反事实方法,假设黑人与白人女性雌激素受体(ER)表达分布相等和/或乳腺癌死亡风险率相等,来检验预期的IBM RRs(BW)。
1990年至2004年期间,死亡率RR(BW)大于1.0且随时间推移而扩大(年龄标准化乳腺癌死亡率从黑人的每10万人36例降至29例,白人从每10万人30例降至22例)。相比之下,发病率RR(BW)通常小于1.0。ER阳性肿瘤的乳腺癌绝对死亡风险率大幅下降,ER阴性肿瘤略有下降,但黑人始终高于白人。使黑人和白人的ER表达分布相等会使IBM RRs(BW)略有下降。有趣的是,当在每个ER类别中匹配乳腺癌死亡风险率时,IBM RRs(BW)的黑人与白人差异基本消除。
年龄标准化乳腺癌死亡率的黑人与白人差异在很大程度上是由患该疾病的黑人女性中较高的乳腺癌死亡风险率驱动的,无论ER表达如何,尤其是在诊断后的头几年。应更加重视确定这些额外风险的病因并制定应对策略。